Does appropriate empiric antibiotic therapy modify intensive care unit-acquired Enterobacteriaceae bacteraemia mortality and discharge? by Pouwels, KB et al.
Pouwels, KB; Van Kleef, E; Vansteelandt, S; Batra, R; Edgeworth,
JD; Smieszek, T; Robotham, JV (2017) Does appropriate empiric
antibiotic therapy modify intensive care unit-acquired Enterobacteri-
aceae bacteraemia mortality and discharge? Journal of Hospital In-
fection, 96 (1). pp. 23-28. ISSN 0195-6701 DOI: https://doi.org/10.1016/j.jhin.2017.03.016
Downloaded from: http://researchonline.lshtm.ac.uk/4651070/
DOI: 10.1016/j.jhin.2017.03.016
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 
 
Does appropriate empiric antibiotic therapy modify ICU-acquired Enterobacteriaceae bacteraemia 1 
mortality and discharge? 2 
 3 
Koen B Pouwels, PhD 
1,2,3
, Esther Van Kleef, PhD 
1,4
, Stijn Vansteelandt, PhD
5
, Rahul Batra, MD
6
, 4 
Jonathan D Edgeworth, MD PhD
6
, Timo Smieszek, PhD
1,3*
, Julie V Robotham, PhD
1*
   5 
 6 
*
 Contributed equally as last authors 7 
 8 
Affiliations: 9 
1. Modelling and Economics Unit, National Infection Service, Public Health England, London, United 10 
Kingdom 11 
2. PharmacoTherapy, -Epidemiology & -Economics, Department of Pharmacy, University of 12 
Groningen, Groningen, The Netherlands 13 
3. MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, 14 
Imperial College School of Public Health, London, United Kingdom 15 
4. Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand 16 
5. Department of Applied Mathematics, Computer Science and Statistics, Faculty of Sciences, Ghent 17 
University, Ghent, Belgium 18 
6. Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, King's 19 
College London and Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom 20 
 21 
 22 
 23 
 24 
 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2 
 
Corresponding author: 26 
Koen B. Pouwels, Modelling and Economics Unit, National Infection Service, Public Health England, 27 
61 Colindale Ave, London NW9 5EQ, United Kingdom; email: koen.pouwels@phe.gov.uk; phone: +44 28 
(0)20 8327 6377 29 
 30 
 31 
 32 
Running title: ICU-acquired bacteraemia and antibiotics 33 
 34 
35 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
Background: Conflicting results have been found regarding outcomes of intensive care unit (ICU)-36 
acquired Enterobacteriaceae bacteraemia and the potentially modifying effect of appropriate 37 
empiric antibiotic therapy.  38 
 39 
Aim: We therefore evaluate these associations while adjusting for potential time-varying 40 
confounding using methods from the causal inference literature.   41 
 42 
Methods: Patients who stayed >2 days in 2 general ICUs in England between 2002 and 2006 were 43 
included in this cohort study. Marginal structural models with inverse probability weighting were 44 
used to estimate the mortality and discharge associated with Enterobacteriaceae bacteraemia and 45 
the impact of appropriate empiric antibiotic therapy on these outcomes. 46 
 47 
Findings: Among 3,411 ICU admissions, 195 (5.7%) ICU-acquired Enterobacteriaceae bacteraemia 48 
occurred. Enterobacteriaceae bacteraemia was associated with an increased daily risk of ICU death 49 
(cause-specific hazard ratio [HR], 1.48; 95% confidence interval [CI], 1.10-1.99) and a reduced daily 50 
risk of ICU discharge (HR, 0.66; 95% CI, 0.54-0.80). Appropriate empiric antibiotic therapy did not 51 
significantly modify ICU mortality (HR 1.08; 95% CI, 0.59-1.97) or discharge (HR 0.91; 95% CI, 0.63-52 
1.32).    53 
 54 
Conclusion: ICU-acquired Enterobacteriaceae bacteraemia was associated with an increased daily 55 
risk of ICU mortality. Furthermore, the daily discharge rate was also lower after acquiring infection, 56 
even when adjusting for time-varying confounding using appropriate methodology. We found no 57 
evidence for a beneficial modifying effect of appropriate empiric antibiotic therapy on ICU mortality 58 
and discharge. 59 
 60 
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 61 
Introduction 62 
Bacteraemia is estimated to affect approximately 1.2 million people in Europe each year, of which 63 
up to 35% have a nosocomial-onset.
1
 Particularly in intensive care unit (ICU) settings, patients have 64 
an elevated risk of acquiring bacteraemia due to the severity of their illness and frequent use of 65 
invasive procedures, such as central line catheterisation.
2
  66 
 67 
Enterobacteriaceae are common causative pathogens of bacteraemia.
3
 None of the studies that 68 
evaluated ICU-acquired Enterobacteriaceae bacteraemia outcomes
2,4,5
 have addressed potential 69 
confounding by time-varying factors using appropriate methodology. The severity of illness of 70 
patients may be both a cause and effect of acquiring Enterobacteriaceae. Standard regression 71 
methods have been shown to be inadequate to account for such complex patterns of time-varying 72 
confounding by severity of illness; alternative solutions have been proposed instead, such as inverse 73 
probability weighting.
6-10
 Because of the lack of studies that make use of such methods, it is not clear 74 
to what extent patients die due to or only with ICU-acquired Enterobacteriaceae bacteraemia. 75 
 76 
While several studies indicate that, especially among critically ill patients, appropriate empiric 77 
treatment for bacteraemia is associated with reduced mortality,
11-19
 many other studies did not find 78 
a protective effect.
20-30
 Several analyses combined community- and hospital-acquired bacteraemia, 79 
adjusting for potential confounders measured at admission and/or at the day of bacteraemia onset, 80 
but did not use all available daily information about patients between admission and acquiring the 81 
bacteraemia.  82 
 83 
Here, we evaluate the impact of Enterobacteriaceae bacteraemia on ICU discharge and mortality, 84 
adjusting for potential time-varying confounding using inverse probability weighting. In addition, we 85 
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estimate the influence of appropriate empiric antibiotic treatment on these outcomes using the 86 
same methodology.  87 
 88 
 89 
 90 
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Methods 92 
Patient data 93 
Clinical records of all patients admitted to one of two general ICUs at Guy’s and St Thomas’ Hospitals 94 
(London, UK) between 2002 and 2006 were obtained. Patients with an ICU length of stay of less than 95 
3 days were excluded. From the remaining cohort, we excluded patients with a blood culture 96 
positive for Enterobacteriaceae during the first 2 days in the ICU, to exclude community-acquired 97 
cases. Age, gender, type of admission (surgical or medical), and ICU ward were recorded at ICU 98 
admission. The following variables were recorded at baseline and subsequently on a daily basis: 99 
Acute Physiology and Chronic Health Evaluation (APACHE) II score, receipt of systemic 100 
antimicrobials, mechanical ventilation, central lines, and renal replacement therapy. In addition, we 101 
obtained admission, discharge and mortality data, and microbial culture and sensitivity test results. 102 
The effect of the first ICU-acquired microbiological proven Enterobacteriaceae bacteraemia was 103 
modelled. Patients were considered to have received appropriate empiric treatment if they were 104 
prescribed one or more systemic doses of one or more antibiotics to which the organism cultured 105 
was sensitive in vitro on the day the blood culture was taken.
20 
106 
 107 
Marginal structural model  108 
Marginal structural models along with inverse probability weighting were used to adjust for 109 
confounding by severity of illness.  110 
In particular, a pseudo-population was constructed by reweighting patients in the risk set on each 111 
day (all patients who did not acquire Enterobacteriaceae bacteraemia in one of the previous days) by 112 
the inverse of the product of the conditional probabilities of the observed infection status before 113 
that day, given the history of time-varying confounders.
7-9
 After weighting, a pseudo-population 114 
remains in which there is no further time-varying confounding by the considered confounders. To 115 
additionally estimate the effect of appropriate empiric antibiotic therapy on ICU mortality and 116 
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discharge, we multiplied the obtained weights for infected patients, from the time of infection 117 
onwards, by the reciprocal of the conditional probability that their bacteraemia was appropriately 118 
treated or not, given time-varying confounders on the previous day. These weights were calculated 119 
as described in Appendix 1.  120 
 121 
 122 
The marginal structural model was fitted using weighted Cox proportional hazard regression with 123 
robust standard errors, thereby accounting for ICU mortality and discharge being competing events. 124 
We included the baseline variables used for stabilization of the weights in the final model, to take 125 
into account possible residual confounding by those variables.
31
 To evaluate the effect of 126 
Enterobacteriaceae bacteraemia, we included a time-varying indicator which was zero before 127 
infection and one from the time of infection onwards. The model that was used to estimate the 128 
effect of appropriate empiric treatment additionally included an indicator for appropriate treatment, 129 
which equalled one if a patient received appropriate empiric antibiotic treatment and zero if the 130 
patient either received inappropriate empiric treatment or not (yet) acquired Enterobacteriaceae 131 
bacteraemia. 132 
 133 
Although there were no missing values at baseline, there were missing values for the APACHE II 134 
score in 3.7% of the subsequent days. Those missing values were imputed using the last observation 135 
carried forward method.   136 
 137 
All models were built using R version 3.2.1 (R Foundation for Statistical Computing, Vienna, Austria; 138 
packages “ipw”, “splines”, ”survival”, ”zoo”). The proportional hazard assumption was evaluated 139 
graphically by plotting weighted Schoenfeld residuals for all proportional hazards models.  140 
 141 
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Scenario analysis 142 
Despite extensive confounding adjustment, appropriate treatment may still be a marker of more-143 
severe infection. To assess whether this may, indeed, be the case, we evaluated whether patients 144 
with more severe infections were more likely to receive appropriate empiric antibiotic treatment. 145 
Severe Enterobacteriaceae bacteraemia was defined by the clinical presence of at least three of the 146 
following indicators: i) respiratory rate of 22/min or greater; ii) systolic blood pressure of 100mm Hg 147 
or less; iii) temperature >38.5°C; iv) white blood cell count >15,000/mm
3
.  148 
Further adjustment for the severity of infection measured on the day the blood culture was taken 149 
could also bias the results, as severity markers may actually be measured after initiation of – and 150 
hence affected by – (in)appropriate empiric antibiotic therapy. Therefore, we fitted a logistic 151 
regression model among patients with Enterobacteriaceae bacteraemia and compared the odds of 152 
receiving appropriate treatment for severe versus non-severe Enterobacteriaceae bacteraemia, 153 
while adjusting for covariates measured the day before acquiring the bacteraemia.  154 
 155 
 156 
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Results 158 
In total, 3,121 patients were included in the study, contributing 3,411 ICU admissions with a length 159 
of stay of at least 3 days and without having a blood culture positive for Enterobacteriaceae during 160 
the first two days in the ICU. Among those 3,411 ICU admissions, 195 (5.7%) ICU-acquired 161 
Enterobacteriaceae bloodstream infections occurred. In 173 (88.7%) cases, only one type of 162 
Enterobacteriaceae was isolated from the blood, while for 20 cases 2 (10.3%), and for 2 cases 3 (1%) 163 
different types were isolated. The isolated microorganisms were Escherichia coli (n=63), 164 
Enterobacter spp. (n=57), Klebsiella spp. (n=50), Proteus spp. (n=23), Serratia spp. (n=19) and 165 
Citrobacter spp. (n=7). Median time from ICU admission to bacteraemia onset was 10 (25th – 75th 166 
percentile, 7-17) days.  167 
 168 
Patient characteristics on admission are shown in Table I. The crude ICU mortality risk of patients 169 
that acquired Enterobacteriaceae bacteraemia was 40.0% compared to 19.5% for patients who did 170 
not. Median unadjusted length of stay in the ICU was 22 days (25th-75th percentile, 14-40) for 171 
patients acquiring bacteraemia and 7 days (25th – 75th percentile, 4-13) for patients who remained 172 
bacteraemia-free.  173 
 174 
Using a marginal structural model, ICU-acquired Enterobacteriaceae bacteraemia was associated 175 
with an increased daily risk of death in the ICU (cause-specific hazard ratio [HR], 1.48; 95% 176 
confidence interval [CI], 1.10-1.99) (Table II). The daily risk of ICU discharge was reduced (cause-177 
specific HR, 0.66; 95% CI, 0.54-0.80), thereby increasing the length of stay and therefore the overall 178 
number of ICU deaths.  179 
When extreme weights are generated, inference using marginal structural models is less reliable.
6,7
 180 
The inverse probability weights used in our marginal structural models had a median and mean of 181 
0.99 and 0.99, an interquartile range and standard deviation of 0.03 and 0.19, a minimum of 0.13 182 
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and maximum of 3.24. These values indicate that our analyses are not negatively affected by 183 
extreme weights. 184 
 185 
Appropriate empiric antibiotic treatment  186 
Of all bacteraemia cases caused by Enterobacteriaceae (n=195), 74 (38%) received appropriate 187 
empiric antibiotic treatment at the day the blood sample was taken. Of those appropriate empiric 188 
antibiotic treatment courses, 92% were with at least one of six antibiotics (gentamicin, ceftazidime, 189 
ciprofloxacin, piperacillin/tazobactam, meropenem and amikacin) recommended in local guidelines 190 
(Appendix 2).
32
 Of all patients who did not receive appropriate empiric treatment on the day of 191 
infection (n=121), 73 (60%) did receive appropriate treatment at some point during their stay. A 192 
switch to appropriate antibiotic treatment occurred for 79% of these patients within 2 days, 193 
indicating that if a change was made, it was usually done based on clinical symptoms and before the 194 
full microbiological test results, particularly susceptibility test results, were available. In our analysis 195 
we only took into account whether treatment was appropriate on the day the sample was taken.  196 
 197 
Appropriate treatment was not significantly associated with the daily risk of ICU mortality (cause-198 
specific HR 1.08; 95% CI, 0.59-1.97) or ICU discharge (cause-specific HR 0.91; 95% CI, 0.63-1.32). The 199 
weights used to reweight the patient population had a median and mean of 0.99 and 1.00, an 200 
interquartile range and standard deviation of 0.03 and 0.24 (min. 0.14, max. 5.21).  201 
  202 
Secondary analysis showed that severe infections were not associated with an increased odds of 203 
receiving appropriate empiric antibiotics (adjusted odds ratio, 1.09; 95% CI, 0.59-2.01).   204 
 205 
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Discussion 207 
In this study, ICU-acquired Enterobacteriaceae bacteraemia had a substantial impact on ICU 208 
mortality. Moreover, the daily discharge rate was also substantially lower among patients that 209 
acquired such an infection, even after adjusting for time-varying confounding using a marginal 210 
structural model. Additional length of stay and ICU mortality associated with ICU-acquired 211 
Enterobacteriaceae bacteraemia was irrespective of initial empiric treatment, i.e. whether this was 212 
appropriate or inappropriate.  213 
 214 
When interpreting the results, it should be noted that our analysis assessed the influence of 215 
acquiring Enterobacteriaceae bacteraemia versus not acquiring it on clinical outcomes. Information 216 
about bacteraemia caused by other pathogens was ignored. A direct comparison of effect estimates 217 
with other studies evaluating the effect of ICU-acquired Enterobacteriaceae bacteraemia is difficult 218 
due to different clinical settings, focus on specific bacteria belonging to the Enterobacteriaceae 219 
family, and different methodology.  220 
 221 
We found no evidence for initial appropriate empiric antibiotic therapy being associated with ICU 222 
mortality or length of stay. Our findings are in line with several recent studies that did not find an 223 
association between inappropriate antibiotic therapy and mortality.
20-30
 A recent prospective 224 
evaluation of empiric antibiotic therapy and mortality in ten English acute hospitals did not find an 225 
association between inappropriate empiric antibiotic therapy and mortality at 7 or 30 days (adjusted 226 
OR 0.82; 95% CI 0.35-1.94 and adjusted OR 0.92; 95% CI 0.50-1.66, respectively).
20
 In that study, it 227 
was suggested that the contrasting results with the older literature may reflect advances in 228 
supportive care, changes in patient mix and differences in the main antibiotic classes used.
20
 Another 229 
factor that may contribute to the contrasting results in the literature is the substantial variation in 230 
methodological quality of different studies.
13
  231 
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 232 
We evaluated whether more severe infections were more likely to receive appropriate empirical 233 
treatment. However, we found no evidence for severe infections being associated with appropriate 234 
empiric treatment. Unfortunately, the data were too limited to be able to assess whether 235 
appropriate empiric treatment is only effective in severely ill patients or other subgroups.
17
  236 
 237 
Another explanation of the absence of a protective effect may be that the majority of switches to 238 
appropriate treatment occurred within 2 days after the blood sample was taken. Hence, changes or 239 
escalation of therapy, if necessary from a clinical perspective, were typically done without 240 
knowledge of microbiological test results and based on clinical assessment. Such switches may have 241 
occurred timely enough to prevent potential detrimental effects of initial inappropriate empiric 242 
treatment. This has also been observed in a randomized controlled trial evaluating the potential 243 
impact of rapid diagnostic tests, where escalation of therapy often happened before the full lab 244 
results were available.
33
 Although not powered to assess mortality and length of stay, that trial did 245 
not observe lower mortality rates or higher discharge rates among patients in the rapid diagnostic 246 
test arms, despite a shorter time to first appropriate antibiotic escalation.
33
  247 
 248 
Strengths and limitations 249 
This is the first study evaluating the effect of ICU-acquired Enterobacteriaceae bacteraemia on ICU 250 
discharge and mortality, while addressing confounding by the evolution of disease prior to infection 251 
using appropriate methodology. Data were available for several years, providing sufficient power to 252 
focus on Enterobacteriaceae instead of all Gram-negative bacteria grouped together.  253 
 254 
Although we took into account as much information as possible and applied advanced statistical 255 
methodology to correct for confounding, several limitations must be acknowledged.  256 
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Despite marginal structural models allowing appropriate adjustment for time-varying confounding, 257 
these techniques remain vulnerable to unmeasured or residual confounding. For example, urinary 258 
focus may be associated with more resistance and hence more likely inappropriate treatment and at 259 
the same time be associated with less severe outcomes than other foci.
20
 This may have resulted in 260 
an underestimation of the beneficial effect of appropriate empiric antibiotic therapy.  261 
We evaluated ICU discharge and mortality in the ICU, but follow-up beyond the ICU would have 262 
been necessary to fully capture the effect of ICU-acquired Enterobacteriaceae bacteraemia on 263 
mortality or total hospital stay.  264 
 265 
Appropriateness of empiric antibiotic treatment was determined based on in vitro susceptibility 266 
tests. However, treatment classified as inappropriate potentially had some activity in vivo.
20
 267 
Likewise, in vitro susceptibility does not guarantee susceptibility in vivo.  268 
  269 
Due to data limitations in records of more recent years, we had to restrict our analysis to the years 270 
2002-2006. Since then, the number of Enterobacteriaceae bacteraemia cases resistant to the most 271 
commonly used antibiotics has increased.
3
 Although this might result in selection of appropriate 272 
empiric antibiotic therapy being more difficult in recent years compared with our period of study,  273 
this would unlikely substantially affect the modifying effect of appropriate empiric antibiotic therapy 274 
itself.    275 
 276 
Preferably, for future analysis, a large multi-centre prospective study will be performed, collecting 277 
information about all potential confounders at baseline and during the ICU-stay. Robust estimates 278 
can be obtained by analysing such data using inverse probability weighting for marginal structural 279 
models, G-estimation for structural nested models, or G-computation.
6
  280 
 281 
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ICU-acquired Enterobacteriaceae bacteraemia was associated with an increased daily risk of ICU 282 
mortality. Furthermore, the daily discharge rate was also lower after acquiring infection, even when 283 
adjusting for time-varying confounding using marginal structural models. When taking into account 284 
daily information about patients between ICU admission and acquiring bacteraemia using 285 
appropriate methodology, these associations were not modified by appropriate empiric antibiotic 286 
treatment. Although our results do not exclude a beneficial impact of empiric antibiotic therapy on 287 
ICU mortality and discharge, they suggest the health-economic benefit of rapid diagnostic testing in 288 
the ICU setting may be less than initially anticipated and may rely mostly on reductions in antibiotic 289 
use and resulting resistance. 290 
 291 
292 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
15 
 
Funding 293 
Financial support. This research was supported by the National Institute for Health Research (NIHR) 294 
Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College 295 
London, programme of Infection and Immunity (RJ112/N027)  awarded to JE,  and the NIHR 296 
Collaboration for Leadership in Applied Health Research and Care (CLAHRC) South London at King's 297 
College Hospital NHS Foundation Trust, awarded to JE and RB. 298 
 299 
Conflicts of interest: None  300 
 301 
302 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
16 
 
References  303 
1. Goto M, Al-Hasan MN. Overall burden of bloodstream infection and nosocomial bloodstream 304 
infection in North America and Europe. Clin Microbiol Infect 2013;19:501-509.  305 
2. Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and 306 
antimicrobial resistance in patients admitted to European intensive-care units: A cohort study. 307 
Lancet Infect Dis 2011;11:30-38.  308 
3. ESPAUR writing committee, public health England. English surveillance programme for 309 
antimicrobial utilisation and resistance (ESPAUR) 2010 to 2014. Report 2015. Available at: 310 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/477962/ESPAUR_311 
Report_2015.pdf. Accessed November 3 2016. 312 
4. Vandijck DM, Depaemelaere M, Labeau SO, et al. Daily cost of antimicrobial therapy in patients 313 
with intensive care unit-acquired, laboratory-confirmed bloodstream infection. Int J Antimicrob 314 
Agents 2008;31:161-165.  315 
5. Ko HK, Yu WK, Lien TC, et al. Intensive care unit-acquired bacteremia in mechanically ventilated 316 
patients: Clinical features and outcomes. PLoS One 2013;8:e83298.  317 
6. Vansteelandt S, Joffe M. Structural nested models and g-estimation: The partially realized 318 
promise. Statistical Science 2014;29:707-731.  319 
7. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of 320 
zidovudine on the survival of HIV-positive men. Epidemiology 2000;11:561-570.  321 
8. Bekaert M, Vansteelandt S, Mertens K. Adjusting for time-varying confounding in the 322 
subdistribution analysis of a competing risk. Lifetime Data Anal 2010;16:45-70.  323 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
9. Vansteelandt S, Mertens K, Suetens C, Goetghebeur E. Marginal structural models for partial 324 
exposure regimes. Biostatistics 2009;10:46-59.  325 
10. Bekaert M, Benoit D, Decruyenaere J, Stijn Vansteelandt. Reply to wolkewitz et al. Intensive Care 326 
Med 2010;36:550.  327 
11. Leibovici L, Shraga I, Drucker M, Koningsberger H, Samra Z, Pitlik SD. The benefit of appropriate 328 
empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998;244:379-329 
386.  330 
12. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial 331 
treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-332 
155.  333 
13. Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-334 
analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents 335 
Chemother 2010;54:4851-4863.  336 
14. Tumbarello M, Sali M, Trecarichi EM, et al. Bloodstream infections caused by extended-337 
spectrum-beta-lactamase- producing Escherichia coli: Risk factors for inadequate initial antimicrobial 338 
therapy. Antimicrob Agents Chemother 2008;52:3244-3252.  339 
15. Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with 340 
bloodstream infections caused by extended-spectrum-beta-lactamase-producing 341 
Enterobacteriaceae: Importance of inadequate initial antimicrobial treatment. Antimicrob Agents 342 
Chemother 2007;51:1987-1994.  343 
16. Valles J, Rello J, Ochagavia A, Garnacho J, Alcala MA. Community-acquired bloodstream infection 344 
in critically ill adult patients: Impact of shock and inappropriate antibiotic therapy on survival. Chest 345 
2003;123:1615-24.  346 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
18 
 
17. Cain SE, Kohn J, Bookstaver PB, Albrecht H, Al-Hasan MN. Stratification of the impact of 347 
inappropriate empirical antimicrobial therapy for Gram-negative bloodstream infections by 348 
predicted prognosis. Antimicrob Agents Chemother 2015;59:245-250.  349 
18. Marchaim D, Gottesman T, Schwartz O, et al. National multicenter study of predictors and 350 
outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing 351 
extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2010;54:5099-5104.  352 
19. Ortega M, Marco F, Soriano A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: 353 
Predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J 354 
Antimicrob Chemother 2009;63:568-574.  355 
20. Fitzpatrick JM, Biswas JS, Edgeworth JD, et al. Gram-negative bacteraemia; a multi-centre 356 
prospective evaluation of empiric antibiotic therapy and outcome in English acute hospitals. Clin 357 
Microbiol Infect 2016;22:244-251.  358 
21. Anderson DJ, Moehring RW, Sloane R, et al. Bloodstream infections in community hospitals in 359 
the 21st century: A multicenter cohort study. PLoS One 2014;9:e91713.  360 
22. Corona A, Bertolini G, Lipman J, Wilson AP, Singer M. Antibiotic use and impact on outcome from 361 
bacteraemic critical illness: The BActeraemia Study in Intensive Care (BASIC). J Antimicrob 362 
Chemother 2010;65:1276-1285.  363 
23. Frakking FN, Rottier WC, Dorigo-Zetsma JW, et al. Appropriateness of empirical treatment and 364 
outcome in bacteremia caused by extended-spectrum-beta-lactamase-producing bacteria. 365 
Antimicrob Agents Chemother 2013;57:3092-3099.  366 
24. Rodriguez-Bano J, Picon E, Gijon P, et al. Risk factors and prognosis of nosocomial bloodstream 367 
infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. J Clin Microbiol 368 
2010;48:1726-1731.  369 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
 
25. Kang CI, Kim SH, Park WB, et al. Bloodstream infections due to extended-spectrum beta-370 
lactamase-producing Escherichia coli and Klebsiella pneumoniae: Risk factors for mortality and 371 
treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 372 
2004;48:4574-4581.  373 
26. Chung HC, Lai CH, Lin JN, et al. Bacteremia caused by extended-spectrum-beta-lactamase-374 
producing Escherichia coli sequence type ST131 and non-ST131 clones: Comparison of demographic 375 
data, clinical features, and mortality. Antimicrob Agents Chemother 2012;56:618-622.  376 
27. De Rosa FG, Pagani N, Fossati L, et al. The effect of inappropriate therapy on bacteremia by ESBL-377 
producing bacteria. Infection 2011;39:555-561.  378 
28. Wang SS, Lee NY, Hsueh PR, et al. Clinical manifestations and prognostic factors in cancer 379 
patients with bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli or 380 
Klebsiella pneumoniae. J Microbiol Immunol Infect 2011;44:282-288.  381 
29. Pena C, Pujol M, Ardanuy C, et al. An outbreak of hospital-acquired Klebsiella pneumoniae 382 
bacteraemia, including strains producing extended-spectrum beta-lactamase. J Hosp Infect 383 
2001;47:53-59.  384 
30. Daikos GL, Kosmidis C, Tassios PT, et al. Enterobacteriaceae bloodstream infections: Presence of 385 
integrons, risk factors, and outcome. Antimicrob Agents Chemother 2007;51:2366-2372.  386 
31. Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am 387 
J Epidemiol 2008;168:656-664.  388 
32. Edgeworth JD, Chis Ster I, Wyncoll D, Shankar-Hari M, McKenzie CA. Long-term adherence to a 5 389 
day antibiotic course guideline for treatment of intensive care unit (ICU)-associated Gram-negative 390 
infections. J Antimicrob Chemother 2014;69:1688-1694.  391 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
20 
 
33. Banerjee R, Teng CB, Cunningham SA, et al. Randomized trial of rapid multiplex polymerase chain 392 
reaction-based blood culture identification and susceptibility testing. Clin Infect Dis 2015;61:1071-393 
1080.394 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
21 
 
 395 
 396 
Table I. Baseline characteristics and crude length of stay and ICU-mortality rates for patients with 397 
and without ICU-acquired Enterobacteriaceae bacteraemia 398 
 Patients with bacteraemia 
(n=195) 
Patients without bacteraemia 
(n=3,216) 
Male sex, n (%) 131 (67.2) 1,966 (61.1) 
Age, mean (SD) 63.1 (14.11) 60.7 (17.11) 
APACHE II, mean (SD) 20.1 (6.4) 18.2 (6.5) 
Admission type 
  Medicine, n (%) 
  Surgery, n (%) 
 
121 (62.1) 
74 (37.9) 
 
1,964 (61.1) 
1,252 (38.9) 
ICU length of stay, median (Q1, Q3) 22 (14, 40) 7 (4, 13) 
ICU mortality, n (%) 78 (40.0) 627 (19.5) 
Abbreviations:  ICU, intensive care unit; SD, standard deviation. 399 
 400 
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 402 
Table II. ICU-acquired Enterobacteriaceae bacteraemia outcomes and influence of appropriate 403 
empiric antibiotic therapy 404 
 ICU mortality CSHR (95% CI) ICU discharge CSHR (95% CI) 
Enterobacteriaceae 
bacteraemia
a 
1.48 (1.10-1.99) 0.66 (0.54-0.80) 
Appropriate empiric antibiotic 
treatment
b 
1.08 (0.59-1.97) 0.91 (0.63-1.32) 
Abbreviations: CI, confidence interval; CSHR, cause-specific hazard ratio; ICU, intensive care unit. 405 
a 
The final model estimating the stabilized weights  for Enterobacteriaceae bacteraemia at each day included the Acute 406 
Physiology and Chronic Health Evaluation (APACHE) II score,  the presence of central lines and antibiotic administration as 407 
time-varying covariates. These weights were stabilized by including gender as a baseline covariate. 408 
b
 The final model estimating the stabilized inverse probability weights for appropriate empiric antibiotic treatment included 409 
the APACHE II score and the presence of central lines as time-varying covariates. These inverse probabilities were stabilized 410 
by including the APACHE II score at admission as a baseline covariate. The final stabilized weights were subsequently 411 
obtained by multiplying the daily stabilized weights for Enterobacteriaceae bacteraemia with the daily stabilized inverse 412 
probabilities for appropriate empiric antibiotic therapy.   413 
414 
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Appendix 1. Calculation of the inverse probability weights. 415 
To calculate the inverse probability weights, daily probabilities of acquiring Enterobacteriaceae 416 
bacteraemia given baseline and time-varying covariates were estimated by using pooled logistic 417 
regression models; these probabilities were set to 1 from the time of bacteraemia onwards. To avoid 418 
large weights, we included baseline covariates in the numerator weights and then later also in the 419 
marginal structural model.
38
 We considered all previously listed variables in the model.  420 
We allowed for a non-linear effect of time by using restricted cubic splines. Non-linear effects of 421 
other continuous covariates, i.e. age, APACHE II score and number of systemic antibiotics at each 422 
day, were allowed in the model by including quadratic terms. In addition, we allowed for 2-way 423 
interactions between (i) APACHE II score at admission and subsequent daily APACHE II score 424 
measurements, and (ii) type of admission and daily APACHE II scores. To build parsimonious models, 425 
we first added all main effects to the model and sequentially removed them if nonsignificant at the 426 
5% level. Next, the suggested interaction terms and non-linear effects were sequentially added if 427 
significant at the 5% level. Similar estimates for the probability that the Enterobacteriaceae 428 
bacteraemia of infected patients were appropriately treated were calculated. The obtained 429 
probabilities were then used to generate daily patient-specific weighing factors.    430 
431 
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Appendix 2. Table I. Appropriate antibiotic therapy for ICU-acquired Enterobacteriaceae 432 
bacteraemia 433 
Appropriate empiric antibiotic therapy  at day of 
first positive blood sample taken (n=74)
a
 
N (%) 
Amikacin 14 (19) 
Amikacin + co-amoxiclav  1 (1) 
Amikacin + colistin 1 (1) 
Ceftazidime 10 (14) 
Ceftazidime + gentamicin 3 (4) 
Cefuroxime 3 (4) 
Ciprofloxacin 8 (11) 
Co-amoxiclav 1 (1) 
Colistin 2 (3) 
Gentamicin 25 (34) 
Piperacillin/tazobactam 6 (8) 
a 
Only antibiotics shown for which the bacteria were susceptible on the day of the blood sample was taken. E.g. if a patient 434 
received both gentamicin and meropenem, but the bacteria were only sensitive to gentamicin, it is shown as monotherapy 435 
with gentamicin. At the time of the study local guidelines recommended a single antibiotic course for all ICU-acquired 436 
gram-negative infections. All patients with severe sepsis or septic shock were recommended to receive a single dose of 437 
gentamicin if a non-aminoglycoside antibiotic course was selected.  438 
 439 
